Xtant Medical Holdings, Inc. (XTNT): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of XTNT were reported in the last 12 months.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who owns XTNT
32 funds and institutions reported XTNT shares worth $62.6M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Nantahala Capital Management, LLC with 97.7%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 136.79M | 97.66% | $57.6M | +100% |
| AWM Investment Company, Inc. | 5.98M | 4.27% | $2.5M | No change |
| Vanguard Capital Management LLC | 2.01M | 1.44% | $848K | No change |
| Renaissance Technologies LLC | 935,119 | 0.67% | $394K | -5% |
| Geode Capital Management, LLC | 517,133 | 0.37% | $218K | -2% |
| Crescent Grove Advisors, LLC | 412,024 | 0.29% | $173K | No change |
| Nano Cap New Millennium Growth Fund L P | 400,000 | 0.29% | $168K | +14% |
| Vanguard Fiduciary Trust Co | 257,988 | 0.18% | $109K | No change |
| Citadel Advisors LLC | 191,369 | 0.14% | $80.6K | +19% |
| Acadian Asset Management LLC | 180,299 | 0.13% | $73K | No change |
| Bridgeway Capital Management, LLC | 164,100 | 0.12% | $69.1K | No change |
| Wiregrass Investment Management LLC | 150,000 | 0.11% | $63.1K | +46% |
| BlackRock, Inc. | 115,782 | 0.08% | $48.7K | No change |
| Mink Brook Asset Management LLC | 109,466 | 0.08% | $46.1K | No change |
| Northern Trust Corp | 101,127 | 0.07% | $42.6K | +2% |
| Millennium Management LLC | 84,490 | 0.06% | $35.6K | -36% |
| XTX Topco Ltd | 68,531 | 0.05% | $28.9K | +81% |
| UBS Group AG | 31,920 | 0.02% | $13.4K | New |
| State Street Corp | 31,266 | 0.02% | $13.2K | No change |
| Sei Investments Co | 24,760 | 0.02% | $10.4K | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No XTNT insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
XTNT short interest
Low short interest. 0.3% of XTNT shares are sold short: about 1 share in 374. Over the last 12 reports the number of shares short went up 1829%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 375,281 XTNT shares were sold short, 0.3% of the shares outstanding, up 24.9% from the report before. At the average daily volume of 97,274 shares, buying them all back would take about 3.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 375,281 | 0.27% | +25% | 97,274 | 3.9 |
| Oct 15, 2026 | 300,482 | 0.21% | +109% | 92,193 | 3.3 |
| Sep 30, 2026 | 143,564 | 0.10% | -47% | 239,833 | 1.0 |
| Sep 15, 2026 | 268,742 | 0.19% | -85% | 1.31M | 1.0 |
| Aug 31, 2026 | 1.83M | 1.30% | +1668% | 8.03M | 1.0 |
| Aug 14, 2026 | 103,406 | 0.07% | +16% | 232,810 | 1.0 |
| Jul 31, 2026 | 88,962 | 0.06% | +27% | 51,996 | 1.7 |
| Jul 15, 2026 | 70,049 | 0.05% | +2059% | 138,637 | 1.0 |
| Jun 30, 2026 | 3,245 | 0.00% | +107% | 59,123 | 1.0 |
| Jun 15, 2026 | 1,568 | 0.00% | -59% | 106,636 | 1.0 |
| May 29, 2026 | 3,862 | 0.00% | -80% | 183,166 | 1.0 |
| May 15, 2026 | 19,453 | 0.01% | -72% | 159,209 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Xtant Medical Holdings company events
Xtant Medical Holdings filed 8 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Aug 11, 2026.
- Aug 11, 2026ResultsReleased financial results. Filing
- Aug 7, 2026VoteReported shareholder vote results. Filing
- May 13, 2026AnnouncementThe Company announced August 7, 2026 as the date of the Company’s 2026 Annual Meeting of Stockholders. Filing
- Apr 13, 2026AnnouncementXtant entered into the Distribution Agreement with Dilon on April 10, 2026, and in connection therewith, hired approximately 20 Dilon sales personnel to assist in the sale of the HEMOBLAST ® Bellows product in the United States. Filing
- Mar 31, 2026ResultsReleased financial results. Filing
- Mar 2, 2026AnnouncementAs previously announced, on December 1, 2025, Xtant Medical Holdings, Inc. sold certain assets relating to its Coflex and CoFix products and all of the outstanding capital stock of its wholly owned subsidiary engaged in the operation of the Company’s hardware business outside of the United States… Filing
- Jan 16, 2026AnnouncementAs previously announced, on December 1, 2025, Xtant Medical Holdings, Inc. and Surgalign SPV, Inc., a wholly owned subsidiary of the Company (together with the Company, the “Seller”), completed the sale of certain assets relating to the Company’s Coflex and CoFix products to Companion Spine, LLC… Filing
- Dec 3, 2025DealXtant Medical Holdings, Inc. and Surgalign SPV, Inc., a wholly owned subsidiary of the Company (together with the Company, the “Seller”), completed the sale of certain assets relating to the Company’s Coflex and CoFix products to Companion Spine, LLC and one of its affiliates, Companion Spine SAS… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Xtant Medical Holdings financials
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named XTNT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Lawrence W. Lytton | 13G/A | 6.5% |
| Nov 16, 2026 | Lawrence W. Lytton | 13G/A | 6.5% |
Questions about Xtant Medical Holdings, Inc. (XTNT) stock
Who owns the most XTNT stock?
The largest reported owner of Xtant Medical Holdings, Inc. (XTNT) is Nantahala Capital Management, LLC, with 97.7% of the company. In total, 32 funds and institutions reported holding XTNT at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are XTNT insiders buying or selling?
No XTNT insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in XTNT?
As of Oct 30, 2026, 375,281 XTNT shares were sold short, 0.3% of the shares outstanding, up 24.9% from the report before. At the average daily volume of 97,274 shares, buying them all back would take about 3.9 trading days (days to cover). See the history.
Executive pay
Xtant Medical Holdings's chief executive was paid a total of $1.4M for the year ended Dec 31, 2025, down 45% from $2.5M the year before. In the last 12 months, Xtant Medical Holdings's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.